Advertisement

Emergency Radiology

, Volume 24, Issue 2, pp 139–142 | Cite as

Gallbladder opacification on gadoxetate disodium-enhanced CT scan

  • Adib R. Karam
  • Eduardo Scortegagna
  • Byron Y. Chen
  • Carolyn S. Dupuis
  • Dennis D. Coughlin
Original Article
  • 177 Downloads

Abstract

This study aimed to evaluate the radiologist’s ability to identify excreted gadoxetate disodium within the gallbladder on CT scan. Thirty three healthy adults underwent imaging of the liver during work-up for potential liver donation. Three patients had undergone prior cholecystectomy and therefore were excluded. Imaging consisted of gadoxetate disodium-enhanced magnetic resonance cholangiography (MRC) and multiphase contrast-enhanced CT scan of the abdomen and pelvis. Two fellowship-trained abdominal imaging radiologists, who were blinded to the MRC images and the contrast agent used during MRC, independently reviewed the CT scans of the 30 patients that were included. The scans were evaluated for the presence or absence of abnormal hyperdensity within the gallbladder. Three patients did not receive intravenous gadoxetate disodium, 4 patients had their MRC after the CT scan, and 1 patient had the CT scans 5 days following the MRC. Twenty two patients had the CT scan within 24 h following the gadoxetate disodium-enhanced MRC. Of the 22 patients expected to have gadolinium in the gallbladder, both reviewers identified hyperdensity in the same 20 patients (90%). Both reviewers reported no abnormal hyperdensity within the gallbladder in the remaining 10 patients. CT scan can reveal excreted gadoxetate disodium within the gallbladder lumen and therefore gadoxetate disodium-enhanced CT scan can potentially play a role in the evaluation of cystic duct patency and work-up of acute cholecystitis.

Keywords

Gallbladder Cystic duct Acute cholecystitis CT scan Gadoxetate disodium 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This study was not funded; no grants were received.

Disclosures

None of the authors (Adib R. Karam, MD; Eduardo Scortegagna, MD; Byron Y. Chen, MD; Carolyn S. Dupuis, MD; and Dennis D. Coughlin, MD) have anything to disclose.

IRB statement

Study received approval from our Institutional Review Board (IRB) and informed consent was waived due to its retrospective nature.

References

  1. 1.
    Elwood DR (2008) Cholecystitis. Surg Clin North Am 88:1241–1252 viiiCrossRefPubMedGoogle Scholar
  2. 2.
    Strasberg SM (2008) Clinical practice. Acute calculous cholecystitis. N Engl J Med 358:2804–2811CrossRefPubMedGoogle Scholar
  3. 3.
    Karam AR, Kim YH, Corwin MT (2013) Gadoxetate disodium-enhanced liver MRI: gallbladder opacification patterns during hepatobiliary phase. Clin Imag. doi: 10.1016/j.clinimag.2013.09.005 Google Scholar
  4. 4.
    Corwin MT, Karam AR, Baker SP, Kim YH (2012) Determination of cystic duct patency using hepatobiliary MRI with gadoxetate disodium: is T1 precontrast imaging necessary? J Magn Reson Imaging 35(3):601–606. doi: 10.1002/jmri.22841 CrossRefPubMedGoogle Scholar
  5. 5.
    Yacoub JH, Yousuf A, Agrawal G, Thomas S, Appelbaum DE, Oto A. Evaluation of the gallbladder and cystic duct patency with gadoxetate disodium enhanced MR cholangiography: prospective comparison of patients with normal gallbladder function and acute cholecystitis. Acta Radiol. 2014.Google Scholar
  6. 6.
    Corwin MT, Lamba R, McGahan JP (2013) Functional MR cholangiography of the cystic duct and sphincter of Oddi using gadoxetate disodium: is a 30-minute delay long enough? J Magn Reson Imaging 37(4):993–998CrossRefPubMedGoogle Scholar

Copyright information

© American Society of Emergency Radiology 2016

Authors and Affiliations

  • Adib R. Karam
    • 1
  • Eduardo Scortegagna
    • 1
  • Byron Y. Chen
    • 1
  • Carolyn S. Dupuis
    • 1
  • Dennis D. Coughlin
    • 1
  1. 1.Radiology DepartmentUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations